IMU 4.26% 4.5¢ imugene limited

Ann: Imugene doses first patient in HER-Vaxx phase 2 trial, page-13

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 588 Posts.
    lightbulb Created with Sketch. 68
    Yes very true.

    Imugene Managing Director and Chief Executive Officer Leslie Chong said, “There is strong medical investigator interest following the good results seen in the recently completed Phase 1b trial, where11 out of 14 evaluable patients showed clinically meaningful responses. We look forward toproviding regular recruitment updates as the Phase 2 study moves toward completion in 2020.”
    Last edited by QiQi: 14/03/19
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
4.5¢
Change
-0.002(4.26%)
Mkt cap ! $386.7M
Open High Low Value Volume
4.7¢ 4.8¢ 4.4¢ $890.8K 19.42M

Buyers (Bids)

No. Vol. Price($)
2 176601 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 969572 8
View Market Depth
Last trade - 16.10pm 06/11/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.